Chordia Therapeutics is a bio-venture company with the slogan of “Building a world where tomorrow is another day” and aims to achieve this by delivering the world’s first made-in-Japan new anti-cancer drugs to patients as soon as possible. Our professionals have long been engaged in drug discovery and are striving every day to develop new drugs that may determine the future of cancer treatment by making use of their knowledge, experience, and expertise in their respective areas of research and development (R&D).
As you know, it takes long hours, a substantial amount of money, and enormous manpower to roll out new drugs. The Company values speedy R&D, which is made possible with our quick decision-making and judgment skills; skills that I believe are unique to a bio-venture. We also appreciate our external partners and shareholders who are supportive of our work. The Company’s name, Chordia, originates from the English term “chord.” The name indicates our desire to develop new cancer drugs efficiently, with the thoughts of our internal and external members coming together to produce a beautiful sound of harmony.
We appreciate all of our shareholders for understanding the challenges faced by the Company in developing new drugs. Our current strength lies in R&D, but our vision is to become an R&D-oriented pharmaceutical company in the near future, by making inroads into the manufacturing and domestic sale of drugs.
We will maximize profits by using the Company’s strengths and characteristics, developing innovative new drugs, and selling them ourselves, and we will use the profits to conduct new R&D so we can help the Company enjoy significant growth. We appreciate your continued support.
